This webinar highlights the opportunity for the exquisite selectivity of enzymatic biotransformations, conducted in vitro or in vivo, to overcome these challenges of tomorrow’s small molecule pharmaceutical manufacturing.
Ingenza recently welcomed Lisa Fraser as the company’s first Senior Project Manager. Lisa brings extensive leadership and project management experience to her new role, and she will no doubt be instrumental in driving Ingenza’s strategic goals and supporting its pioneering work in…
The use of enzymes as catalysts in chemical reactions offer several advantages for pharmaceutical manufacturing over traditional chemical production routes. Benefits include high selectivity, product purity and mild reaction conditions that reduces energy consumption and waste whilst removing the use…
Ingenza has partnered with Oxford-based biotech company HydRegen to develop a more sustainable and cost-effective method for manufacturing amine-based chemicals, eliminating the need for heavy metal catalysts. The company turned to Ingenza to help improve the expression levels of a new candidate biocatalyst,…
Thanks for joining us – if you would like to re-watch the webinar, the video has been made available below to watch again. Over the past two decades, the biopharma community has faced significant challenges in advancing exciting and potentially…
Ingenza – a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator – is delighted to announce its plans to relocate to the Moubray Building at Edinburgh Technopole, part of Pioneer Group. Following a detailed strategic review, the company has embarked on…
Biomanufacturing uses biological systems to produce commercially relevant molecules– such as peptides, proteins, antibodies and small molecules – at scale. Choosing the ideal host organism is crucial for an efficient and economical bioprocess, and mammalian cell lines and Escherichia coli are currently the…
Many COVID-19 vaccines work by presenting fragments of the SARS-CoV-2 spike protein – the receptor-binding domain (RBD) – to the body to generate an immune response. However, newly arising SARS-CoV-2 variants are increasingly able to evade this response due to…
Enzyme evolution can be used to take a wild-type enzyme that is in some way unsuitable for a bioprocess of interest and create a strain with enhanced capabilities. This iterative process is based on the design-build-test-learn (DBTL) cycle,1 and can be used…
Cell line development is a critical aspect of biotechnology and pharmaceutical research, and plays an important role in Ingenza’s CRDMO services. The process involves establishing and maintaining genetically identical mammalian cells in culture for use in a variety of processes, such…